Abstract
Background: Management of antihistamine refractory chronic idiopathic urticaria (CIU) has poorly defined therapeutic options. Objective: To evaluate the efficacy of dapsone (4,4'-diaminodiphenylsulfone) in antihistamine refractory CIU compared with placebo. Methods: Twenty-two patients with antihistamine refractory CIU were randomly assigned to 100 mg of dapsone daily or placebo for 6 weeks in a 14-week double-blind, placebo-controlled crossover trial. End points were measured from a daily diary that reflected the weekly hive score, the weekly itch score, and a visual analog scale (VAS) score. Secondary to a carryover effect, the first period results were analyzed as a parallel design that compared placebo with dapsone directly by using repeated-measures analysis. Results: After 6 weeks, the patients in the dapsone arm showed mean improvement over baseline in VAS (2.3 [95% CI, 0.6-4.1], P= .01), urticaria score (-3.5 [95% CI, -6.2 to -0.9], P= .01), and itch score (-4.8 [95% CI, -7.6 to -2.1], P= .001), whereas the placebo arm showed no improvement over baseline for VAS, urticaria, or itch scores. Dapsone showed greater improvement compared with placebo for itch (P= .047) and VAS (P= .04). Of the 22 patients, 3 showed complete resolution of hives and itch with dapsone, whereas 31% and 41% had ≥50% resolution of hives and itch, respectively. No serious adverse effects were observed with dapsone. Conclusion: To our knowledge, this is the first double-blind, placebo controlled study of dapsone in CIU and indicates that dapsone has efficacy in patients with antihistamine refractory CIU.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 601-606 |
| Number of pages | 6 |
| Journal | Journal of Allergy and Clinical Immunology: In Practice |
| Volume | 2 |
| Issue number | 5 |
| DOIs | |
| State | Published - 2014 |
Fingerprint
Keywords
- Antihistamine
- Chronic idiopathic urticaria
- Dapsone
- RCT
- Urticaria
ASJC Scopus subject areas
- Immunology and Allergy
Cite this
Double-Blind Placebo-Controlled Trial of Dapsone in Antihistamine Refractory Chronic Idiopathic Urticaria. / Morgan, Matt; Cooke, Andrew; Rogers, Laura; Adams-Huet, Beverley; Khan, David A.
In: Journal of Allergy and Clinical Immunology: In Practice, Vol. 2, No. 5, 2014, p. 601-606.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Double-Blind Placebo-Controlled Trial of Dapsone in Antihistamine Refractory Chronic Idiopathic Urticaria
AU - Morgan, Matt
AU - Cooke, Andrew
AU - Rogers, Laura
AU - Adams-Huet, Beverley
AU - Khan, David A.
PY - 2014
Y1 - 2014
N2 - Background: Management of antihistamine refractory chronic idiopathic urticaria (CIU) has poorly defined therapeutic options. Objective: To evaluate the efficacy of dapsone (4,4'-diaminodiphenylsulfone) in antihistamine refractory CIU compared with placebo. Methods: Twenty-two patients with antihistamine refractory CIU were randomly assigned to 100 mg of dapsone daily or placebo for 6 weeks in a 14-week double-blind, placebo-controlled crossover trial. End points were measured from a daily diary that reflected the weekly hive score, the weekly itch score, and a visual analog scale (VAS) score. Secondary to a carryover effect, the first period results were analyzed as a parallel design that compared placebo with dapsone directly by using repeated-measures analysis. Results: After 6 weeks, the patients in the dapsone arm showed mean improvement over baseline in VAS (2.3 [95% CI, 0.6-4.1], P= .01), urticaria score (-3.5 [95% CI, -6.2 to -0.9], P= .01), and itch score (-4.8 [95% CI, -7.6 to -2.1], P= .001), whereas the placebo arm showed no improvement over baseline for VAS, urticaria, or itch scores. Dapsone showed greater improvement compared with placebo for itch (P= .047) and VAS (P= .04). Of the 22 patients, 3 showed complete resolution of hives and itch with dapsone, whereas 31% and 41% had ≥50% resolution of hives and itch, respectively. No serious adverse effects were observed with dapsone. Conclusion: To our knowledge, this is the first double-blind, placebo controlled study of dapsone in CIU and indicates that dapsone has efficacy in patients with antihistamine refractory CIU.
AB - Background: Management of antihistamine refractory chronic idiopathic urticaria (CIU) has poorly defined therapeutic options. Objective: To evaluate the efficacy of dapsone (4,4'-diaminodiphenylsulfone) in antihistamine refractory CIU compared with placebo. Methods: Twenty-two patients with antihistamine refractory CIU were randomly assigned to 100 mg of dapsone daily or placebo for 6 weeks in a 14-week double-blind, placebo-controlled crossover trial. End points were measured from a daily diary that reflected the weekly hive score, the weekly itch score, and a visual analog scale (VAS) score. Secondary to a carryover effect, the first period results were analyzed as a parallel design that compared placebo with dapsone directly by using repeated-measures analysis. Results: After 6 weeks, the patients in the dapsone arm showed mean improvement over baseline in VAS (2.3 [95% CI, 0.6-4.1], P= .01), urticaria score (-3.5 [95% CI, -6.2 to -0.9], P= .01), and itch score (-4.8 [95% CI, -7.6 to -2.1], P= .001), whereas the placebo arm showed no improvement over baseline for VAS, urticaria, or itch scores. Dapsone showed greater improvement compared with placebo for itch (P= .047) and VAS (P= .04). Of the 22 patients, 3 showed complete resolution of hives and itch with dapsone, whereas 31% and 41% had ≥50% resolution of hives and itch, respectively. No serious adverse effects were observed with dapsone. Conclusion: To our knowledge, this is the first double-blind, placebo controlled study of dapsone in CIU and indicates that dapsone has efficacy in patients with antihistamine refractory CIU.
KW - Antihistamine
KW - Chronic idiopathic urticaria
KW - Dapsone
KW - RCT
KW - Urticaria
UR - http://www.scopus.com/inward/record.url?scp=84925108209&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84925108209&partnerID=8YFLogxK
U2 - 10.1016/j.jaip.2014.06.004
DO - 10.1016/j.jaip.2014.06.004
M3 - Article
VL - 2
SP - 601
EP - 606
JO - Journal of Allergy and Clinical Immunology: In Practice
JF - Journal of Allergy and Clinical Immunology: In Practice
SN - 2213-2198
IS - 5
ER -